Find Academic Supervisors

Professor Thomas Bein is affiliated with the Department of Chemistry at Ludwig-Maximilians-Universität München (LMU) , where he leads the Functional Nanosystems research group. His work focuses on synthesizing and characterizing nanostructured materials with applications in energy, catalysis, and biomedical delivery. Mesoporous nanoparticles for drug delivery Semiconductor nano-morphologies for photovoltaics Photoelectrochemical water splitting Metal-organic frameworks (MOFs) Electroactive networks His research emphasizes atomic-scale control of material architectures using self-assembly, hydrogen bonding, and covalent interactions, enabling precise tuning of electronic, optical, and catalytic properties. A review of his recent publications reveals cutting-edge investigations into covalent organic frameworks (COFs), perovskite-inspired solar materials, and functional nanoparticle systems. Key trends include optimizing energy conversion efficiency, enhancing stability in optoelectronic devices, and exploring bio-compatible nanocarriers for targeted therapies. Professor Bein’s group actively contributes to interdisciplinary projects at the intersection of chemistry, physics, and biomedical engineering, with ongoing collaborations in solar energy, sustainable materials, and nanomedicine.

• Nanotechnology
• Materials Science
• Photovoltaics
• +4 more

Harris H. Wang is an Associate Professor in the Department of Systems Biology and Department of Pathology and Cell Biology at Columbia University's Vagelos College of Physicians and Surgeons, where he also serves as Interim Chair of Systems Biology. He is affiliated with the Center for Computational Biology and Bioinformatics (C2B2) and the Integrated Program in Cellular, Molecular and Biomedical Studies (CMBS). B.S., Physics and Mathematics, MIT Ph.D., Biophysics, Harvard University Dr. Wang's research lies at the intersection of systems and synthetic biology, focusing on developing foundational technologies for genome engineering, microbiome manipulation, and synthetic genomics. His lab pioneers methods such as MAGE, MAGIC, CAST, and CAMII to enable high-throughput genetic manipulation, in situ microbiome engineering, and AI-driven microbial culturomics. Key research themes include understanding microbial community dynamics, engineering cellular memory systems, designing biocontained genetic circuits, and applying synthetic biology to human health challenges in personalized medicine and infectious disease. His recent publications reveal a strong trend in spatial and functional metagenomics, CRISPR-based microbiome editing, and synthetic biology tools for data storage and genetic stability. The articles span high-impact journals like Nature , Science , and Nature Biotechnology , reflecting his leadership in developing scalable, programmable biological systems. Scientific Awards: NIH Director’s Early Independence Award Forbes 30 Under 30 in Science Sloan Research Fellowship NSF CAREER Award ONR Young Investigator Award Burroughs Wellcome Fund PATH Award Schaefer Scholar Blavatnik National Award Vilcek Prize PECASE Dr. Wang has advised numerous PhD and postdoctoral researchers, many of whom have gone on to independent scientific careers. His lab is supported by major grants from NIH, NSF, DARPA, DOE, and foundations including the Bill & Melinda Gates Foundation and CZ Biohub NY. He is actively involved in educational initiatives, including organizing Columbia’s iGEM team and the Cold Spring Harbor Laboratory Synthetic Biology course. The Wang Lab is based at the Columbia University Irving Medical Center and is part of national consortia such as the Engineering Biology Research Consortium (EBRC) and the Genome Project-Write (GP-Write) initiative. The lab develops and applies cutting-edge technologies in automation, machine learning, and synthetic biology to engineer microbiomes for applications in medicine, global health, and climate change.

• Systems Biology
• Synthetic Biology
• Genome Engineering
• +17 more

Dr. Jimeng Sun is a Health Innovation Professor at the Siebel School of Computing and Data Science and Carle Illinois College of Medicine at the University of Illinois Urbana-Champaign. Co-founder of Keiji AI , he leads groundbreaking research at the intersection of artificial intelligence and healthcare, actively deploying clinical AI systems and developing frameworks like PyHealth and Therapeutics Data Commons . His research spans four major areas: Clinical AI Systems : Developing interpretable models (e.g., RETAIN) for patient similarity, temporal event prediction, medication recommendation, and clinical outcome forecasting Drug Discovery : Creating molecular optimization frameworks, drug-target interaction models, and AI-driven platforms Clinical Trials : Pioneering patient-trial matching, outcome prediction, and optimization frameworks using deep learning and graph neural networks Biosignal Analysis : Advancing sleep staging, seizure classification, and automated EEG/Cardiac monitoring systems With over 500 top-tier publications (including in Nature , NEJM AI , and leading AI conferences) and an h-index of 99, his work has been recognized with the Top 100 AI Leaders in Drug Discovery and Advanced Healthcare award. He maintains active collaborations with institutions like Massachusetts General Hospital , Medidata Solutions , and OSF Healthcare . His recent publications reveal a strong focus on: Reinforcement learning applications in medical data analysis Large language model adaptation for clinical tasks Knowledge graph integration with AI systems Synthetic data generation for healthcare Multi-modal learning in clinical contexts Explainable AI for medical applications Dr. Sun's lab ( Sunlab ) emphasizes practical impact over theoretical work, actively collaborating with hospitals and healthtech companies. He welcomes contributions from clinicians, researchers, and industry partners through initiatives like his AI for Health webinar series .

• Artificial Intelligence
• Healthcare Analytics
• Drug Discovery
• +5 more

Sriram Subramaniam is a Professor in the Department of Biochemistry and Molecular Biology at the University of British Columbia (UBC) and holds the Gobind Khorana Canada Excellence Research Chair in Precision Cancer Drug Design. His research leverages cryo-electron microscopy (cryo-EM) to advance structural biology and drug design, focusing on protein dynamics and therapeutic target identification. Education: PhD in Physical Chemistry (1987) from Stanford University; MSc in Chemistry (1981) from Indian Institute of Technology, Kanpur. Subramaniam's interdisciplinary work combines cryo-EM with computational tools and molecular biology to study protein structures at atomic resolution. His lab has pioneered cryo-EM applications in precision medicine, including mapping small molecule drugs on patient-specific cancer mutants. Recent publications (2024-2022) highlight his contributions to understanding SARS-CoV-2 immune evasion, structural mechanisms of ATPases, and AI integration in structural biology. His research spans viral entry mechanisms, CRISPR systems, and neurodegenerative disease pathways. Scientific Awards: Gobind Khorana Canada Excellence Research Chair NIH Director’s Award for Scientific Excellence Fellow of the Biophysical Society Breakthrough Prize nomination Based at the Djavad Mowafaghian Center for Brain Health, Subramaniam leads the Program in Cryo-EM Guided Drug Design, contributing to over 177 peer-reviewed publications with a career h-index of 58 and citations exceeding 12,340.

• cryo-electron microscopy
• structural biology
• drug-design
• +4 more

Daniel Finley is a Professor of Cell Biology at Harvard Medical School (HMS), leading the Finley Lab focused on the ubiquitin-proteasome pathway and related regulatory mechanisms. He holds academic appointments within the Department of Cell Biology and sits on the Scientific Advisory Boards of Proteostasis and X-Chem Pharmaceuticals. His research investigates proteasome function, ubiquitin-like proteins, and proteostasis roles in diseases like Alzheimer’s and ALS. Dr. Finley earned his undergraduate degree in biochemistry from Harvard University and a Ph.D. in molecular biology from MIT. After postdoctoral training at MIT, he joined HMS in 1988. His lab explores topics including erythroid proteome remodeling, mitochondrial dysfunction, and neurodegenerative disease mechanisms. Key research areas include: (1) Ubiquitin-proteasome pathway regulation, (2) Proteasome structure/function, (3) Nonproteolytic roles of ubiquitination, and (4) Pathophysiological roles of proteostasis defects in diseases. His work bridges basic cell biology with translational medicine, particularly in neurodegeneration and anemia. Finley has secured NIH funding for projects like 'Regulation of Proteasome Activity' (R35GM145246) and 'Erythrocyte maturation through global proteome remodeling' (R01HL153970). Collaborations with industry and academic partners extend his impact in drug discovery and proteasome-targeted therapies. His lab’s contributions include defining ubiquitin chain editing mechanisms, identifying USP14’s role in mitophagy, and elucidating proteostasis defects in Alzheimer's models. Research tools developed include advanced cryo-EM analyses of proteasomal structures and functional assays for ubiquitin system enzymes.

• Ubiquitin-Proteasome Pathway
• Proteostasis
• Protein Degradation
• +7 more

Pierre Vandergheynst is a Full Professor at the Swiss Federal Institute of Technology Lausanne (EPFL) in the Department of Electrical Engineering, with a courtesy appointment in Computer and Communication Sciences. He serves as EPFL’s Vice-Provost for Education since 2015 and leads the Signal Processing Laboratory 2 (LTS2). His research spans harmonic analysis, sparse approximations, mathematical data processing, and applications in signal/image processing, computer vision, machine learning, and graph-based data analysis. PhD in Mathematical Physics (1998), Université catholique de Louvain Postdoctoral Researcher at EPFL (1998-2001) Assistant Professor at EPFL (2002-2007) His research explores geometry/symmetry in high-dimensional data, redundant dictionaries for dimensionality reduction, and computational harmonic analysis on manifolds. Recent work focuses on protein structure modeling, geometric deep learning, and graph-based signal processing. Key article trends include graph neural networks for protein analysis, geometric deep learning in neuroscience, and structured knowledge priors in neural models. His 2023-2025 publications emphasize interpretable AI, long-range dependencies in graphs, and molecular representation learning. Scientific Awards: IEEE Signal Processing Magazine Best Paper Award (2023) Signal Processing Society Best Paper Award (2022) Apple ARTS Award (2007) De Boelpaepe Prize, Royal Academy of Sciences of Belgium (2009-2010) He has supervised over 30 PhD theses and contributed to foundational work in graph signal processing, compressive sensing, and geometric deep learning. His lab develops tools for data science on non-Euclidean structures, with applications in medicine, astronomy, and wireless systems.

• Data Science
• Machine Learning
• Computational Harmonic Analysis
• +6 more

Petros Koumoutsakos is the Herbert S. Winokur, Jr. Professor of Computing in Science and Engineering at Harvard University's School of Engineering and Applied Sciences (SEAS), where he also serves as Area Chair for Applied Mathematics. His research integrates machine learning with computational science to advance understanding of complex systems, including fluid dynamics, turbulence modeling, and biomedical applications. He leads the CSE Lab, focusing on high-performance computing and interdisciplinary collaborations such as a recent study with Citadel Securities and Google Cloud to simulate heart disease in cloud environments. Key research interests include reinforcement learning for turbulence closures, generative models for PDE solutions, and physics-informed AI for biomedical imaging and wildfire prediction. He was awarded the PRACE HPC Excellence Award (2023) for contributions to high-performance computing. His work bridges computational methods with real-world applications, emphasizing interpretability and scalability in multiscale systems. Grants & Collaborations: Leadership in multi-institutional projects, including turbulence modeling via reinforcement learning and cloud-based HPC studies. Labs/Teams: Director of the CSE Lab, advancing AI, computational fluid dynamics, and biomedical simulations.

• Machine Learning
• Computational Fluid Dynamics
• Turbulence Modeling
• +3 more

Bradley D. Olsen is a full professor in the Department of Chemical Engineering at the Massachusetts Institute of Technology (MIT), where he leads research at the intersection of polymer science, soft matter physics, and bioengineering. His work focuses on designing materials for critical applications in biotechnology, hemostasis, and sustainable polymer development while advancing fundamental understanding of polymer network mechanics and self-assembly. Education: Ph.D. in Chemical Engineering, University of California Berkeley (2007) S.B. in Chemical Engineering, Massachusetts Institute of Technology (2003) Olsen's research spans protein-based materials, block copolymer phase behavior, and mechanochemical hydrogels. He has pioneered methods for quantifying polymer network topology, developing hemostatic nanoparticles, and creating bio-inspired materials for selective biomolecular transport and medical applications. His recent publications emphasize data-driven approaches to polymer characterization and educational outreach in materials science. Scientific Awards: American Physical Society (APS) Fellow (2023) Fulbright Amazonia Scholar (2023) Alexander and I. Michael Kasser Chair in Chemical Engineering (2021) ACS Macro Letters Young Investigator Award (2021) MIT Committed to Caring Honor (2019) AIChE Owens Corning Early Career Award (2019) APS Dillon Medal (2018) Kavli Emerging Leader in Chemistry (2017) ACS Polymer Division Fellow (2016) Camille Dreyfus-Teacher Scholar (2015) Alfred P. Sloan Research Fellow (2014) NSF Career Grant (2013) NIH Postdoctoral Fellowship (2008-2009) Hertz Fellow (2003-2007) Barry M. Goldwater Scholarship (2002) Olsen has received significant grant support including NSF Career (2013) and AFOSR (2012) awards. His teaching activities include innovative international outreach like the 2025 soccer-themed science camp in Brazil. The Olsen Group at MIT explores advanced materials with applications ranging from trauma care to sustainable polymers.

• Polymer Science
• Materials Engineering
• Soft Condensed Matter Physics
• +4 more

Dr. Shyh-Dar Li is a Professor and Tong Louie Chair in Pharmaceutical Sciences at the University of British Columbia's Faculty of Pharmaceutical Sciences, where he also serves as Chair of Nanomedicine and Chemical Biology. With a BSc in pharmacy from National Taiwan University (1998) and PhD in pharmaceutical sciences from UNC Chapel Hill (2008), followed by postdoctoral training at UC San Diego's Moores Cancer Center (2009), Dr. Li has established himself as a leading researcher in advanced drug delivery systems. His research focuses on developing innovative nanomedicine platforms for targeted delivery of biological therapeutics including peptides, proteins, antibodies, and nucleic acids. Dr. Li's laboratory has pioneered several novel drug delivery approaches, particularly in lipid-based nanoparticles, phospholipid-free vesicles, and polymer systems for cancer immunotherapy, pain management, and protein delivery. His work bridges fundamental nanotechnology with translational applications for difficult-to-treat diseases. Analysis of his recent publications reveals a strong emphasis on tumor microenvironment modulation, endosomal escape mechanisms for nucleic acid delivery, and non-invasive delivery routes for protein therapeutics. His research demonstrates increasing sophistication in nanocarrier engineering, with recent work incorporating machine learning approaches to optimize nanoparticle design and expanding into immunomodulatory therapies that harness the body's immune system to fight cancer. Scientific Recognition: 2014 AFPC New Investigator Award 2013 AAPS New Investigator Award in Pharmaceutics and Pharmaceutical Technologies 2013 CIHR New Investigator Award 2013 CSPS Early Career Award 2012 Prostate Cancer Foundation Young Investigator Award Dr. Li's research program has been consistently supported by major Canadian funding agencies including CIHR, NSERC, and MITACS. He actively collaborates across disciplines and accepts graduate students into his research program, focusing on cutting-edge approaches to overcome biological barriers in drug delivery. His laboratory, the Laboratory of Targeted Drug Delivery and Nanomedicine, serves as a hub for innovation in pharmaceutical nanotechnology.

• Drug Delivery
• Nanomedicine
• Biopharmaceutics
• +7 more

Vikramaditya G. Yadav is an Associate Professor at the University of British Columbia (UBC) in the Department of Chemical and Biological Engineering, Faculty of Applied Science. He directs the Master of Engineering Leadership (MEL) Program in Sustainable Process Engineering and leads the BioFoundry research group. Education: B.A.Sc., University of Waterloo (2007) Ph.D., Massachusetts Institute of Technology (2013) Postdoctoral Associate, Harvard University (2014) His research spans sustainable chemical manufacturing, metabolic engineering, and biotechnology. Key areas include: Designing biosynthetic enzymes for biomass valorization Developing bioremediation strategies for industrial water quality Creating innovative drug delivery systems and tissue engineering solutions Advancing synthetic biology for pharmaceutical and bioenergy applications His recent work focuses on ocular drug delivery, cannabinoid biosynthesis in E. coli, lignin-based nanoparticles for cancer therapy, and computational analysis of plant secondary metabolites. Collaborations with start-ups, industry, and medical labs drive innovation in Canada's bioeconomy. Professional Leadership: Chair, Biotechnology Division of the Chemical Institute of Canada Associate Editor, The Canadian Journal of Chemical Engineering He is affiliated with UBC's BioProducts Institute and contributes to project-based learning pedagogy.

• Biocatalysis
• Bioremediation
• Bioprocess engineering
• +15 more

Michael McAlpine is a Professor in the Mechanical Engineering department at the University of Minnesota . He also holds affiliations with the Biomedical Engineering and Electrical and Computer Engineering departments. His research focuses on 3D printing functional materials & devices , Nanoscale inks , Biomedical devices , Bioelectronics , and Flexible Microsystems . Research Interests : 3D Printing, Biomedical Engineering, Nanotechnology, Flexible Electronics, Microfluidics Labs : ME 361/363 Contact : mcalpine@umn.edu , (612) 626-3303, ME 117 Recent Research Trends include 3D Printed Biomedical Devices , Flexible Electronics , and Bioprinting Applications . His work spans from Spinal Organoid Formation to Programmable Drug Release Capsules . Scientific Award : Circulation Research 2020 Best Manuscript Award

• 3D Printing
• Nanotechnology
• Biomedical Engineering
• +4 more

Wengong Jin is an Assistant Professor at the Khoury College of Computer Sciences, Northeastern University, and a visiting research scientist at the Eric and Wendy Schmidt Center at the Broad Institute. He holds a PhD from MIT CSAIL, advised by Prof. Regina Barzilay and Prof. Tommi Jaakkola. Research Interests: His work focuses on geometric and generative AI models for drug discovery, biology, and chemical engineering. Key areas include equivariant neural networks (e.g., FAFormer), diffusion models for binding energy prediction, antibody/enzyme design (RefineGNN, SurfPro), and molecular design through graph neural networks (Junction Tree VAE). He also explores domain generalization and systems for autonomous molecular discovery. Publications: His research has been published in top venues like NeurIPS, ICLR, ICML, Nature, Science, and Cell. Recent breakthroughs include discovering novel antibiotics using explainable AI and designing synergistic drug combinations for cancer treatment. Awards: He has received the BroadIgnite Award, Dimitris N. Chorafas Prize, and MIT EECS Outstanding Thesis Award for his contributions to computational biology and AI-driven drug discovery. Teaching: Currently teaches a PhD seminar on AI for Science, focusing on integrating machine learning into scientific discovery processes.

• AI for drug discovery
• Generative AI models
• Geometric deep learning
• +5 more

Connor Coley is the Henri Slezynger (1957) Career Development Assistant Professor at the Massachusetts Institute of Technology (MIT) School of Engineering. His research bridges chemistry and machine learning, focusing on autonomous molecular discovery, predictive chemistry, and laboratory automation. Education: Ph.D., MIT (2019) M.S.CEP., MIT (2016) B.S., Caltech (2014) Research Interests: Dr. Coley’s work centers on domain-informed machine learning for chemistry, computer-aided molecular design, and autonomous laboratories. Key themes include predictive modeling of chemical reactivity, optimization of synthesis pathways, and integration of AI with experimental data for drug discovery and materials science. Publications: His recent articles highlight advancements in AI-driven reaction prediction, molecular representation learning, and laboratory automation. Trends include applications of Bayesian optimization, contrastive learning, and diffusion models to chemical discovery. Scientific Awards: Camille Dreyfus Teacher-Scholar Award (2025) James W. Swan Outstanding Faculty (2025) Schmidt Futures AI2050 Early Career Fellow (2022) NSF CAREER Award (2021) Forbes 30 Under 30: Healthcare (2019) Software & Tools: He leads the open-source ASKCOS software suite for synthesis planning, adopted by 35,000+ chemists and deployed at 15+ pharmaceutical companies. His team also develops tools for metabolomics and molecular representation learning.

• Machine Learning for Chemistry
• Computer-Aided Molecular Design
• Synthesis Planning
• +5 more

Rainer Haag is a Professor at the Department of Chemistry, Freie Universität Berlin, leading the Haag Group in the Institute of Chemistry and Biochemistry. His research focuses on biodegradable and sustainable materials, dynamic hydrogels, and polymeric nanosystems for biomedical applications. Department of Chemistry, Freie Universität Berlin Member of SFB 1449: Dynamic Hydrogels at Biointerfaces Collaborator in the StemGel startup project Co-founder of CSR|Berlin interdisciplinary research institute Research Interests: Development of stimuli-responsive polymers, multivalent virus inhibitors, and functional biointerfaces. Key projects include: Antiviral coatings using heteromultivalent polymers Thermoresponsive hydrogels for stem cell expansion Graphene derivatives for bacterial capture and disinfection Lignin upcycling for sustainable resin materials Supramolecular nanosystems for drug delivery Publication Trends highlight interdisciplinary work in polymer chemistry, nanotechnology, and biomedical applications. Recent articles focus on: 2D polyglycerols for virus interactions Redox-responsive nanogels Mucus-inspired adhesive hydrogels Tumor-targeting micelles Bacterial disinfection using graphene composites Labs & Collaborations include the Polymeric and Supramolecular Nanosystems subgroup, the Dynamic Hydrogels and Biointerfaces team, and partnerships with MIT in developing bioinspired adhesives. His group contributes to DFG-funded SFB 1449 and CSR|Berlin initiatives.

• Biodegradable Materials
• Sustainable Polymer Chemistry
• Dynamic Hydrogels
• +7 more

Prof. Paul Stupple is a Professor of Medicinal Chemistry at Monash University, Australia, with over 20 years' experience in pharmaceutical industry and academia. He holds leadership roles at Canthera Discovery and manages the Australian Translational Medicinal Chemistry Facility. His expertise lies in small molecule drug discovery, particularly targeting cancer therapies and epigenetic regulators. Affiliations: Monash University, Faculty of Pharmacy and Pharmaceutical Sciences Canthera Discovery (Director, Medicinal Chemistry) Education: BA and DPhil in Chemistry from the University of Oxford (1992–1999). Early career at Pfizer as a medicinal chemistry leader, delivering 6 clinical candidates. Key contributions include: Licensing deals with Merck (2016) and Pfizer (2018) for preclinical projects Leading the Cancer Therapeutics CRC's medicinal chemistry program Research Interests: Small molecule drug discovery focused on histone acetyltransferase inhibitors, cancer therapeutics, and epigenetic modulation. Notable projects include development of KAT6A/B inhibitors for ER+ breast cancer and STING agonists for immunotherapy. Grants/Projects: Principal Investigator for major initiatives like MedChem Australia (2023–2028) and drug target identification platforms. Collaborates widely with institutions like WEHI and University of Sydney. Over 28 peer-reviewed publications spanning 1997–2025. Labs/Teams: Oversees the Australian Translational Medicinal Chemistry Facility, a key resource for drug discovery in Australia.

• Small Molecule Drug Discovery
• Cancer Therapeutics
• Pharmaceutical Chemistry
• +3 more